Other
Premature Ejaculation
34
Pipeline Programs↗
8
Active Trials↗
17
Companies Involved↗
Premature Ejaculation is a moderately active landscape with 34 programs across 17 companies. The most active players are Endo Pharmaceuticals, Dong-A Pharmaceutical Co., Ltd., Vitae Pharmaceuticals Inc., an Allergan affiliate. 3 therapies are approved with 11 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical5
Phase 213
Phase 311
Analysis
Trial Status
52
clinical trials
Completed29 · 56%
Unknown status12 · 23%
Recruiting4 · 8%
Terminated3 · 6%
Not yet recruiting3 · 6%
Active, not recruiting1 · 2%
Clinical Trials
Trial Activity
52 trials
Hyaluronic Acid vs Botulinum Toxin Injection in Treatment of Lifelong Drug-Resistant Premature Ejaculation: Randomized Study
Not yet recruiting·—·N/A·NCT07236632·80 enrolled
A Study of the Effectiveness and Safety of Dapoxetine in the Treatment of Men With Premature Ejaculation
Completed·
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00229073·1,116 enrolled
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00229073·1,116 enrolledA Study of Withdrawal Effects With Dapoxetine in the Treatment of Premature Ejaculation
Completed·Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00210613·199 enrolled
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00210613·199 enrolled
Page 1 of 4
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)